Reported Earnings • May 26
Full year 2026 earnings released: EPS: ₹3.64 (vs ₹13.89 loss in FY 2025) Full year 2026 results: EPS: ₹3.64 (up from ₹13.89 loss in FY 2025). Revenue: ₹237.2m (down 42% from FY 2025). Net income: ₹18.4m (up ₹88.4m from FY 2025). Profit margin: 7.7% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Annuncio • May 19
National Oxygen Limited to Report Q4, 2026 Results on May 25, 2026 National Oxygen Limited announced that they will report Q4, 2026 results on May 25, 2026 Valuation Update With 7 Day Price Move • May 07
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹81.98, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 7.7% over the past three years. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹67.42, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 27% over the past three years. Annuncio • Mar 21
National Oxygen Limited announced that it expects to receive funding from Saraf Housing Development Private Limited National Oxygen Limited announced a private placement to issue 950,000 shares on March 20, 2026. The transaction will include participation from new investor Saraf Housing Development Private Limited. The transaction has been approved by shareholders of company. Reported Earnings • Jan 31
Third quarter 2026 earnings released: ₹3.08 loss per share (vs ₹3.92 loss in 3Q 2025) Third quarter 2026 results: ₹3.08 loss per share (improved from ₹3.92 loss in 3Q 2025). Revenue: ₹51.5m (down 52% from 3Q 2025). Net loss: ₹15.5m (loss narrowed 21% from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Annuncio • Jan 27
National Oxygen Limited to Report Q3, 2026 Results on Jan 30, 2026 National Oxygen Limited announced that they will report Q3, 2026 results on Jan 30, 2026 Valuation Update With 7 Day Price Move • Jan 07
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹93.46, the stock trades at a trailing P/E ratio of 78.5x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 39% over the past three years. New Risk • Jan 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Negative equity (-₹28m). Market cap is less than US$10m (₹449.3m market cap, or US$4.99m). Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (₹334m revenue, or US$3.7m). Valuation Update With 7 Day Price Move • Dec 23
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹78.65, the stock trades at a trailing P/E ratio of 66x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 54% over the past three years. Valuation Update With 7 Day Price Move • Dec 08
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹95.00, the stock trades at a trailing P/E ratio of 79.7x. Average trailing P/E is 24x in the Chemicals industry in India. Total loss to shareholders of 26% over the past three years. Reported Earnings • Nov 14
Second quarter 2026 earnings released: EPS: ₹13.96 (vs ₹2.35 loss in 2Q 2025) Second quarter 2026 results: EPS: ₹13.96 (up from ₹2.35 loss in 2Q 2025). Revenue: ₹66.2m (down 38% from 2Q 2025). Net income: ₹70.4m (up ₹82.3m from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Annuncio • Nov 07
National Oxygen Limited to Report Q2, 2026 Results on Nov 12, 2025 National Oxygen Limited announced that they will report Q2, 2026 results on Nov 12, 2025 Annuncio • Aug 29
National Oxygen Limited, Annual General Meeting, Sep 24, 2025 National Oxygen Limited, Annual General Meeting, Sep 24, 2025, at 11:30 Indian Standard Time. New Risk • Aug 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹3.7m free cash flow). Negative equity (-₹80m). Earnings have declined by 40% per year over the past 5 years. Market cap is less than US$10m (₹634.1m market cap, or US$7.27m). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Revenue is less than US$5m (₹376m revenue, or US$4.3m). Reported Earnings • Aug 08
First quarter 2026 earnings released: ₹3.71 loss per share (vs ₹2.47 loss in 1Q 2025) First quarter 2026 results: ₹3.71 loss per share (further deteriorated from ₹2.47 loss in 1Q 2025). Revenue: ₹76.4m (down 28% from 1Q 2025). Net loss: ₹18.7m (loss widened 50% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance. Annuncio • Aug 05
National Oxygen Limited to Report Q1, 2026 Results on Aug 07, 2025 National Oxygen Limited announced that they will report Q1, 2026 results on Aug 07, 2025 Reported Earnings • May 31
Full year 2025 earnings released: ₹13.90 loss per share (vs ₹6.41 loss in FY 2024) Full year 2025 results: ₹13.90 loss per share (further deteriorated from ₹6.41 loss in FY 2024). Revenue: ₹408.6m (down 9.7% from FY 2024). Net loss: ₹70.0m (loss widened 117% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 120 percentage points per year, which is a significant difference in performance. Annuncio • May 26
National Oxygen Limited to Report Q4, 2025 Results on May 29, 2025 National Oxygen Limited announced that they will report Q4, 2025 results on May 29, 2025 Reported Earnings • Feb 08
Third quarter 2025 earnings released: ₹3.92 loss per share (vs ₹2.52 loss in 3Q 2024) Third quarter 2025 results: ₹3.92 loss per share (further deteriorated from ₹2.52 loss in 3Q 2024). Revenue: ₹108.5m (down 4.0% from 3Q 2024). Net loss: ₹19.8m (loss widened 63% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 126 percentage points per year, which is a significant difference in performance. New Risk • Feb 03
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: ₹435m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-₹34m). Earnings have declined by 15% per year over the past 5 years. Market cap is less than US$10m (₹607.9m market cap, or US$6.98m). Minor Risk Revenue is less than US$5m (₹435m revenue, or US$5.0m). Annuncio • Jan 29
National Oxygen Limited to Report Q3, 2025 Results on Feb 07, 2025 National Oxygen Limited announced that they will report Q3, 2025 results on Feb 07, 2025 Reported Earnings • Nov 13
Second quarter 2025 earnings released: ₹2.35 loss per share (vs ₹1.26 loss in 2Q 2024) Second quarter 2025 results: ₹2.35 loss per share (further deteriorated from ₹1.26 loss in 2Q 2024). Revenue: ₹106.9m (down 9.5% from 2Q 2024). Net loss: ₹11.9m (loss widened 97% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 151 percentage points per year, which is a significant difference in performance. Annuncio • Nov 09
National Oxygen Limited to Report Q2, 2025 Results on Nov 11, 2024 National Oxygen Limited announced that they will report Q2, 2025 results on Nov 11, 2024 Reported Earnings • Aug 14
First quarter 2025 earnings released: ₹2.47 loss per share (vs ₹1.21 loss in 1Q 2024) First quarter 2025 results: ₹2.47 loss per share (further deteriorated from ₹1.21 loss in 1Q 2024). Revenue: ₹106.3m (down 4.4% from 1Q 2024). Net loss: ₹12.5m (loss widened 115% from 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 143 percentage points per year, which is a significant difference in performance. Annuncio • Aug 13
National Oxygen Limited, Annual General Meeting, Sep 16, 2024 National Oxygen Limited, Annual General Meeting, Sep 16, 2024. Annuncio • Aug 02
National Oxygen Limited to Report Q1, 2025 Results on Aug 13, 2024 National Oxygen Limited announced that they will report Q1, 2025 results on Aug 13, 2024 Reported Earnings • May 23
Full year 2024 earnings released: ₹6.60 loss per share (vs ₹1.65 loss in FY 2023) Full year 2024 results: ₹6.60 loss per share (further deteriorated from ₹1.65 loss in FY 2023). Revenue: ₹457.6m (down 2.9% from FY 2023). Net loss: ₹32.3m (loss widened 309% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 122 percentage points per year, which is a significant difference in performance. New Risk • May 21
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-₹21m). Earnings have declined by 1.5% per year over the past 5 years. Market cap is less than US$10m (₹816.6m market cap, or US$9.80m). Minor Risk Shareholders have been diluted in the past year (5.0% increase in shares outstanding). Annuncio • May 15
National Oxygen Limited to Report Q4, 2024 Results on May 22, 2024 National Oxygen Limited announced that they will report Q4, 2024 results on May 22, 2024 New Risk • Apr 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-₹21m). Earnings have declined by 1.5% per year over the past 5 years. Market cap is less than US$10m (₹673.8m market cap, or US$8.07m). Minor Risk Share price has been volatile over the past 3 months (8.9% average weekly change). Annuncio • Feb 03
National Oxygen Limited to Report Q3, 2024 Results on Feb 09, 2024 National Oxygen Limited announced that they will report Q3, 2024 results on Feb 09, 2024 Annuncio • Jan 22
National Oxygen Limited announced that it expects to receive funding from Saraf Housing Development Private Limited National Oxygen Limited announced a private placement of 240,114 common shares on January 20, 2024. The transaction included participation from new investor Saraf Housing Development Private Limited. The transaction has been approved by the board of directors of the company. Reported Earnings • Nov 09
Second quarter 2024 earnings released: ₹1.26 loss per share (vs ₹2.43 loss in 2Q 2023) Second quarter 2024 results: ₹1.26 loss per share (improved from ₹2.43 loss in 2Q 2023). Revenue: ₹119.3m (up 1.6% from 2Q 2023). Net loss: ₹6.03m (loss narrowed 48% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings. New Risk • Aug 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-₹9.3m). Market cap is less than US$10m (₹587.3m market cap, or US$7.07m). Minor Risk Share price has been volatile over the past 3 months (8.2% average weekly change). Reported Earnings • Aug 06
Full year 2023 earnings released: ₹1.65 loss per share (vs ₹15.88 profit in FY 2022) Full year 2023 results: ₹1.65 loss per share (down from ₹15.88 profit in FY 2022). Revenue: ₹471.1m (down 6.9% from FY 2022). Net loss: ₹7.91m (down 110% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth. Annuncio • Aug 04
National Oxygen Limited to Report Q1, 2024 Results on Aug 11, 2023 National Oxygen Limited announced that they will report Q1, 2024 results on Aug 11, 2023 Annuncio • Aug 03
National Oxygen Limited, Annual General Meeting, Aug 28, 2023 National Oxygen Limited, Annual General Meeting, Aug 28, 2023, at 11:30 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2023 together with the Reports of the Board of Directors and the Auditors thereon; to appoint a director in place of Ms. Sarita Saraf who retires from office by rotation and being eligible offers herself for reappointment; to reappoint Ms. Mona Milan Parekh as independent director of the company for a second term of five consecutive year to reappoint Mr. Rajesh Kumar Saraf as independent director of the company for a second term of five consecutive year; and to consider other matters. Reported Earnings • May 30
Full year 2023 earnings released: ₹1.65 loss per share (vs ₹15.88 profit in FY 2022) Full year 2023 results: ₹1.65 loss per share (down from ₹15.88 profit in FY 2022). Revenue: ₹477.0m (down 6.1% from FY 2022). Net loss: ₹7.91m (down 110% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 46% per year whereas the company’s share price has increased by 48% per year. Annuncio • May 19
National Oxygen Limited to Report Q4, 2023 Results on May 24, 2023 National Oxygen Limited announced that they will report Q4, 2023 results at 3:30 PM, Indian Standard Time on May 24, 2023 Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Amit Agarwal was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 06
Third quarter 2023 earnings released: ₹1.00 loss per share (vs ₹1.44 profit in 3Q 2022) Third quarter 2023 results: ₹1.00 loss per share (down from ₹1.44 profit in 3Q 2022). Revenue: ₹119.2m (flat on 3Q 2022). Net loss: ₹4.83m (down 170% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has only increased by 52% per year, which means it is significantly lagging earnings growth. Annuncio • Jan 26
National Oxygen Limited to Report Q3, 2023 Results on Feb 03, 2023 National Oxygen Limited announced that they will report Q3, 2023 results on Feb 03, 2023 Reported Earnings • Nov 05
Second quarter 2023 earnings released: ₹2.43 loss per share (vs ₹4.00 profit in 2Q 2022) Second quarter 2023 results: ₹2.43 loss per share (down from ₹4.00 profit in 2Q 2022). Revenue: ₹117.7m (down 11% from 2Q 2022). Net loss: ₹11.7m (down 161% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 40% per year, which means it is significantly lagging earnings growth. Annuncio • Oct 27
National Oxygen Limited to Report First Half, 2022 Results on Nov 04, 2022 National Oxygen Limited announced that they will report first half, 2022 results on Nov 04, 2022 Reported Earnings • Jul 26
First quarter 2023 earnings released: EPS: ₹0.04 (vs ₹8.40 in 1Q 2022) First quarter 2023 results: EPS: ₹0.04 (down from ₹8.40 in 1Q 2022). Revenue: ₹114.2m (down 21% from 1Q 2022). Net income: ₹170.0k (down 100% from 1Q 2022). Profit margin: 0.1% (down from 28% in 1Q 2022). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 49% per year, which means it is significantly lagging earnings growth. Annuncio • Jul 26
National Oxygen Limited, Annual General Meeting, Aug 30, 2022 National Oxygen Limited, Annual General Meeting, Aug 30, 2022. Agenda: To discuss the re-appointment of independent director for the second term of five years; to discuss the issue of equity shares on preferential basis to promoter group company alterations of memorandum of association; to discuss the related party transactions; to discuss the directors report and the audit report; and to discuss other matters. Annuncio • Jul 15
National Oxygen Limited to Report Q1, 2023 Results on Jul 25, 2022 National Oxygen Limited announced that they will report Q1, 2023 results at 12:15 PM, Indian Standard Time on Jul 25, 2022 Valuation Update With 7 Day Price Move • Jul 11
Investor sentiment improved over the past week After last week's 15% share price gain to ₹114, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 182% over the past three years. Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment improved over the past week After last week's 17% share price gain to ₹108, the stock trades at a trailing P/E ratio of 6.8x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 167% over the past three years. Annuncio • May 23
National Oxygen Limited Appoints Sarita Saraff as Marketing Head National Oxygen Limited appointed Sarita Saraff as Marketing Head at the Board Meeting held on May 21, 2022. Reported Earnings • May 22
Full year 2022 earnings released: EPS: ₹15.88 (vs ₹2.28 loss in FY 2021) Full year 2022 results: EPS: ₹15.88 (up from ₹2.28 loss in FY 2021). Revenue: ₹520.5m (up 30% from FY 2021). Net income: ₹76.3m (up ₹87.2m from FY 2021). Profit margin: 15% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 40% per year, which means it is significantly lagging earnings growth. Annuncio • May 14
National Oxygen Limited to Report Q4, 2022 Results on May 21, 2022 National Oxygen Limited announced that they will report Q4, 2022 results on May 21, 2022 Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment improved over the past week After last week's 15% share price gain to ₹115, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 211% over the past three years. Valuation Update With 7 Day Price Move • Mar 17
Investor sentiment improved over the past week After last week's 27% share price gain to ₹100, the stock trades at a trailing P/E ratio of 6.3x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 160% over the past three years. Valuation Update With 7 Day Price Move • Mar 02
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹70.45, the stock trades at a trailing P/E ratio of 4.4x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 86% over the past three years. Reported Earnings • Feb 13
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹1.44 (down from ₹2.94 in 3Q 2021). Revenue: ₹118.8m (down 5.8% from 3Q 2021). Net income: ₹6.93m (down 51% from 3Q 2021). Profit margin: 5.8% (down from 11% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹118, the stock trades at a trailing P/E ratio of 6.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 219% over the past three years. Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment improved over the past week After last week's 15% share price gain to ₹128, the stock trades at a trailing P/E ratio of 7.4x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 226% over the past three years. Valuation Update With 7 Day Price Move • Dec 01
Investor sentiment improved over the past week After last week's 20% share price gain to ₹75.80, the stock trades at a trailing P/E ratio of 4.4x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 74% over the past three years. Valuation Update With 7 Day Price Move • Aug 19
Investor sentiment improved over the past week After last week's 21% share price gain to ₹65.10, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 243% over the past three years. Reported Earnings • Aug 15
First quarter 2022 earnings released: EPS ₹8.40 (vs ₹4.77 loss in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹145.1m (up 120% from 1Q 2021). Net income: ₹40.3m (up ₹63.2m from 1Q 2021). Profit margin: 28% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings. Reported Earnings • Feb 10
Third quarter 2021 earnings released: EPS ₹2.94 (vs ₹1.34 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹126.4m (up 15% from 3Q 2020). Net income: ₹14.1m (up ₹20.5m from 3Q 2020). Profit margin: 11% (up from net loss in 3Q 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 63% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Annuncio • Feb 04
National Oxygen Limited to Report Q3, 2021 Results on Feb 09, 2021 National Oxygen Limited announced that they will report Q3, 2021 results on Feb 09, 2021 Is New 90 Day High Low • Jan 28
New 90-day high: ₹46.50 The company is up 21% from its price of ₹38.35 on 26 October 2020. The Indian market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. Is New 90 Day High Low • Dec 02
New 90-day low: ₹36.00 The company is down 9.0% from its price of ₹39.50 on 03 September 2020. The Indian market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period. Reported Earnings • Nov 12
Second quarter 2021 earnings released: ₹2.53 loss per share The company reported a poor second quarter result with weaker earnings, revenues and control over expenses. Second quarter 2021 results: Revenue: ₹90.6m (down 22% from 2Q 2020). Net loss: ₹12.2m (down ₹13.3m from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Sep 18
New 90-day high: ₹43.55 The company is up 20% from its price of ₹36.15 on 19 June 2020. The Indian market is up 14% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 21% over the same period.